Primary hyperparathyroidism: pathophysiology and impact on bone

Khan, Aliya; Bilezikian, John
July 2000
CMAJ: Canadian Medical Association Journal;7/25/2000, Vol. 163 Issue 2, p184
Academic Journal
AbstractPrimary hyperparathyroidism has been associated with bone loss, especially at cortical skeletal sites. Results from studies evaluating the mineral density of cancellous bone have been more difficult to interpret. Most densitometry studies support the concept that the parathyroid hormone appears to be catabolic at cortical sites and may have anabolic effects at cancellous bone sites. Studies completed to date, however, have been limited by design, definitions of fracture and inadequate control groups. Primary hyperparathyroidism is now increasingly being detected during the asymptomatic phase. The need for parathyroidectomy has been questioned in such patients because there may be no disease progression in the absence of surgery. Medical management of primary hyperparathyroidism has to date been limited to estrogen replacement therapy in postmenopausal women. Identification of the calcium receptor has improved our understanding of calcium homeostasis, and significant reductions in calcium receptor levels have been detected in parathyroid adenomas. Thus, a new class of therapeutics may include the calcimimetic agents. Bisphosphonates are also currently being evaluated with regard to their impact on fracture prevention and their beneficial effects on bone mineral density.


Related Articles

  • Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Gourlay, Margaret; Franceschini, Nora; Sheyn, Yevgeniy // Clinical Rheumatology;Feb2007, Vol. 26 Issue 2, p144 

    Glucocorticoids are the most common cause of drug-related osteoporosis. We reviewed current evidence on risk factors for glucocorticoid-induced osteoporosis (GIOP) and prevention and treatment of GIOP-related fractures. Guidelines for GIOP management published since 2000 were also reviewed....

  • Current and future treatment options in osteoporosis. Brewer, Linda; Williams, David; Moore, Alan // European Journal of Clinical Pharmacology;Apr2011, Vol. 67 Issue 4, p321 

    Purpose: The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. Methods: When...

  • European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Kanis, J.; Mccloskey, E.; Johansson, H.; Cooper, C.; Rizzoli, R.; Reginster, J.-y. // Osteoporosis International;Jan2013, Vol. 24 Issue 1, p23 

    Summary: Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis. Introduction: The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis...

  • Vitamin D supplementation in pre-dialysis chronic kidney disease. Alvarez, Jessica A.; Wasse, Haimanot; Tangpricha, Vin // Dermato-Endocrinology;2012, Vol. 4 Issue 2, p118 

    Vitamin D deficiency is associated with a variety of skeletal, cardiometabolic, and immunologic co-morbidities that are present in chronic kidney disease (CKD). We performed a systematic review to investigate the effects of vitamin D supplementation, in the form of ergocalciferol or...

  • Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Zitt, Emanuel; Fouque, Denis; Jacobson, Stefan H.; Malberti, Fabio; Ryba, Miroslav; Ureña, Pablo; Rix, Marianne; Dehmel, Bastian; Manamley, Nick; Vervloet, Marc // Clinical Kidney Journal;Jun2013, Vol. 6 Issue 3, p287 

    Background The calcimimetic cinacalcet lowers parathyroid hormone (PTH), calcium (Ca) and phosphorus (P) in dialysis patients with secondary hyperparathyroidism (SHPT). We explored serum P changes in dialysis patients treated with cinacalcet, while controlling for vitamin D sterol and phosphate...

  • Reoperations for primary hyperparathyroidism-improvement of outcome over two decades. Karakas, Elias; Müller, Hans-Helge; Schlosshauer, Torsten; Rothmund, Matthias; Bartsch, Detlef // Langenbeck's Archives of Surgery;Jan2013, Vol. 398 Issue 1, p99 

    Purpose: Reoperations (R-PTX) for primary hyperparathyroidism (pHPT) are challenging, since they are associated with increased failure and morbidity rates. The aim was to evaluate the results of reoperations over two decades, the latter considering the implementation of Tcsestamibi-SPECT...

  • Osteoporosis: Are Two Drugs Better Than One? Kuritzky, Louis // Infectious Disease Alert;Oct2013 Clincal Briefs, p20 

    The article discusses research being done on whether denosumab plus teriparatide is an effective therapy for osteoporosis in postmenopausal women, which references a study by J. N. Tsai and colleagues published in a 2013 issue of "Lancet."

  • Osteoporosis: Are Two Drugs Better Than One? Kuritzky, Louis // Internal Medicine Alert;9/29/2013 Clinical Briefs, p144 

    The article reports that the combination of two drugs including the Teriparatide (TERI) and the Denosumab (DENO) for the treatment of osteoporosis in woman as these drugs improve the bone mineral density.

  • A Guide to Osteoporosis Medications.  // Healthy Years;Mar2014, Vol. 11 Issue 3, p6 

    The article offers a guide to several medications for osteoporosis. A study published online in the "New England Journal of Medicine" on January 1, 2014 suggests that a new drug called romosozumab may offer hope for the treatment of osteoporosis. Other current treatment options for disease...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics